Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXSNASDAQ:BLCMNASDAQ:CNSPNASDAQ:MACK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.56+1.8%$0.69$0.50▼$1.95$5.97M1.6220,308 shs559 shsBLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsCNSPCNS Pharmaceuticals$0.22+4.8%$0.31$0.19▼$2.98$2.32M2.67359,958 shs109,097 shsMACKMerrimack Pharmaceuticals$14.73$14.71$11.53▼$15.89$214.03M1.43110,102 shs55,162 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals+1.85%-3.51%-22.54%-8.33%-53.39%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%-22.29%-77.74%CNSPCNS Pharmaceuticals-4.67%-0.49%-45.60%-51.39%-88.00%MACKMerrimack Pharmaceuticals+0.14%+0.34%+0.07%+11.17%+21.23%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals2.00HoldN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$10K596.63N/AN/A($2.27) per share-0.24BLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33CNSPCNS PharmaceuticalsN/AN/AN/AN/A($0.71) per shareN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)BLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ACNSPCNS Pharmaceuticals-$18.85M-$5.66N/A∞N/AN/A-603.40%-421.35%5/20/2024 (Estimated)MACKMerrimack Pharmaceuticals-$1.18M-$0.08N/A∞N/AN/A-6.24%-6.09%5/2/2024 (Estimated)Latest MACK, ADXS, BLCM, and CNSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/16/2024Q4 2023ADXSAyala PharmaceuticalsN/A-$2.96-$2.96-$2.96N/AN/A4/1/2024Q4 2023CNSPCNS PharmaceuticalsN/A-$0.95-$0.95-$0.95N/AN/A3/7/2024Q4 2023MACKMerrimack PharmaceuticalsN/A-$0.01-$0.01-$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/A0.300.30BLCMBellicum PharmaceuticalsN/A3.043.04CNSPCNS PharmaceuticalsN/A0.260.26MACKMerrimack PharmaceuticalsN/A43.5043.50OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%BLCMBellicum Pharmaceuticals4.93%CNSPCNS Pharmaceuticals14.02%MACKMerrimack Pharmaceuticals63.97%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%BLCMBellicum Pharmaceuticals10.30%CNSPCNS Pharmaceuticals3.88%MACKMerrimack Pharmaceuticals28.87%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableCNSPCNS Pharmaceuticals310.64 million10.22 millionNot OptionableMACKMerrimack Pharmaceuticals42614.53 million10.34 millionOptionableMACK, ADXS, BLCM, and CNSP HeadlinesSourceHeadlineMACK Merrimack Pharmaceuticals, Inc.seekingalpha.com - April 20 at 8:40 PMMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Passes Above 200 Day Moving Average of $13.50americanbankingnews.com - April 20 at 2:32 AMFrom debilitating disease to the marathoneagletribune.com - April 14 at 6:48 AMDiagonal starts up with $128M to make better ‘activator’ antibody drugsfinance.yahoo.com - April 3 at 4:07 PMMerrimack Receives $225 Million Milestone Payment from Ipsenbusinesswire.com - March 27 at 4:30 PMMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above 200 Day Moving Average of $13.19marketbeat.com - March 26 at 4:11 AMHere are chances Dalton Knecht, Tennessee basketball will be in Memphis for March Madnesstennessean.com - March 12 at 10:27 AMStocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cutsmsn.com - March 8 at 3:41 PMMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023investorplace.com - March 8 at 10:02 AMMerrimack Reports Full Year 2023 Financial Resultsbusinesswire.com - March 7 at 4:30 PMMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the companyfinance.yahoo.com - March 4 at 7:39 AMMerrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, Predictionsbenzinga.com - February 22 at 12:38 PMUnlocking The Potentials Of Liposomal Drug Delivery Device Marketopprairie.com - February 20 at 2:37 AMMACK Mar 2024 14.000 putfinance.yahoo.com - February 17 at 7:50 PMMACK Mar 2024 4.000 putfinance.yahoo.com - February 17 at 2:49 PMOnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officermarkets.businessinsider.com - February 15 at 1:03 PMMerrimack to call it a day after pocketing Ipsen cashthepharmaletter.com - February 15 at 8:02 AMMACK Feb 2024 16.000 putfinance.yahoo.com - February 14 at 8:47 PMFDA Approves New First-Line Med for Pancreatic Cancer as Drug’s Initial Developer Dissolvesmedcitynews.com - February 14 at 8:47 PMIpsen drug approved by FDA for early pancreatic cancerfinance.yahoo.com - February 14 at 3:42 PMThe S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cutsmsn.com - February 13 at 7:31 PMMerrimack Pharmaceuticals to Hold Meeting on Corporate Dissolutionmarketwatch.com - February 13 at 7:31 PMMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)finance.yahoo.com - February 13 at 7:31 PMMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)businesswire.com - February 13 at 4:18 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Bellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.CNS PharmaceuticalsNASDAQ:CNSPCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Merrimack PharmaceuticalsNASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
